New therapies in neurology, but who benefits?
In recent years several new treatments have been introduced in neurology, sumatriptan in migraine, riluzole in amyotrophic lateral sclerosis, interferon-beta in multiple sclerosis and rivastigmine in Alzheimer's disease. Doubts exist on the effects on functional outcome of these new treatments. Hardly effective drugs are not forced on physicians by the pharmaceutical industry, since physicians are involved in decisions from phase I studies to the final approval of the drugs. The problem is, however, that in clinical studies emphasis is still on statistically significant differences rather than on meaningful differences in the functional status of patients. In conclusion, in clinical studies outcome measures should be chosen more carefully and there is a need for sensitive linear functional scales.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1999 |
|---|---|
| Erschienen: |
1999 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
Nederlands tijdschrift voor geneeskunde - 143(1999), 35 vom: 28. Aug., Seite 1764-6 |
| Sprache: |
Niederländisch |
|---|
| Weiterer Titel: |
Nieuwe therapieën in de neurologie, maar wie wordt er beter van? |
|---|
| Beteiligte Personen: |
Vermeulen, M [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 29.10.1999 Date Revised 10.12.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM104253215 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM104253215 | ||
| 003 | DE-627 | ||
| 005 | 20231222132124.0 | ||
| 007 | tu | ||
| 008 | 231222s1999 xx ||||| 00| ||dut c | ||
| 028 | 5 | 2 | |a pubmed24n0348.xml |
| 035 | |a (DE-627)NLM104253215 | ||
| 035 | |a (NLM)10494326 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dut | ||
| 100 | 1 | |a Vermeulen, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New therapies in neurology, but who benefits? |
| 246 | 3 | 3 | |a Nieuwe therapieën in de neurologie, maar wie wordt er beter van? |
| 264 | 1 | |c 1999 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 29.10.1999 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In recent years several new treatments have been introduced in neurology, sumatriptan in migraine, riluzole in amyotrophic lateral sclerosis, interferon-beta in multiple sclerosis and rivastigmine in Alzheimer's disease. Doubts exist on the effects on functional outcome of these new treatments. Hardly effective drugs are not forced on physicians by the pharmaceutical industry, since physicians are involved in decisions from phase I studies to the final approval of the drugs. The problem is, however, that in clinical studies emphasis is still on statistically significant differences rather than on meaningful differences in the functional status of patients. In conclusion, in clinical studies outcome measures should be chosen more carefully and there is a need for sensitive linear functional scales | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Carbamates |2 NLM | |
| 650 | 7 | |a Neuroprotective Agents |2 NLM | |
| 650 | 7 | |a Phenylcarbamates |2 NLM | |
| 650 | 7 | |a Vasoconstrictor Agents |2 NLM | |
| 650 | 7 | |a Interferon-beta |2 NLM | |
| 650 | 7 | |a 77238-31-4 |2 NLM | |
| 650 | 7 | |a Riluzole |2 NLM | |
| 650 | 7 | |a 7LJ087RS6F |2 NLM | |
| 650 | 7 | |a Sumatriptan |2 NLM | |
| 650 | 7 | |a 8R78F6L9VO |2 NLM | |
| 650 | 7 | |a Rivastigmine |2 NLM | |
| 650 | 7 | |a PKI06M3IW0 |2 NLM | |
| 700 | 1 | |a de Haan, R J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nederlands tijdschrift voor geneeskunde |d 1946 |g 143(1999), 35 vom: 28. Aug., Seite 1764-6 |w (DE-627)NLM000034231 |x 1876-8784 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:1999 |g number:35 |g day:28 |g month:08 |g pages:1764-6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 1999 |e 35 |b 28 |c 08 |h 1764-6 | ||